Cystic Fibrosis Market Size, Analysis, Share & Forecast 2031

Cystic Fibrosis Market Size, Analysis, Share & Forecast 2031

Segments - Cystic Fibrosis Market by Diagnosis Types (Sweat Test, Genetic Test, Newborn Screening, Sinus X-rays, Lung Function Tests, Intestinal Current Measurement, Nasal Potential Difference, Sputum Culture, and Chest X-rays), Treatment Methods (Lung Transplant, Bowel Surgery, Feeding Tube, Noninvasive Ventilation, Oxygen Therapy, and Liver Transplant), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2022 – 2030

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vineet
Fact-checked by : Vineet Pandey
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-4192 | 4.4 Rating | 82 Reviews | 155 Pages | Format : PDF Excel PPT

Report Description


The global cystic fibrosis market size was valued at USD 5.16 billion in 2021 and is estimated to reach USD 31.91 billion by 2030, expanding at a CAGR of 24.6% during the forecast period, 2022–2030. The growth of the market is attributed to increasing prevalence of cystic fibrosis across the globe.

Cystic Fibrosis Market_Summary

Cystic Fibrosis (CF) is a hereditary disease that is caused by mutation of genes. Cystic fibrosis disease is caused by mutation in the cystic fibrosis transmembrane conductance regulator gene which is located at chromosome number 7.  Cystic fibrosis transmembrane conductance regulator gene is located in chromosome number 7. Genes control protein secretion of certain liquids in the body and are responsible for the regulation of mucus, sweat, and body secretions. Mutation caused in this gene leads to absence of CFTR activity, which results in alteration of the protein structure and cause loss of chloride. In this disease, the sweat and mucous thicken by affecting various organs in the body. Patients with these conditions face problems such as gastrointestinal system disorder and they suffer with increased infection in lower and upper respiratory tract. Physical therapy aids in the treatment of cystic fibrosis, thus helping to reduce mucous formation. Kalydeco and Pulmozyme drugs are used to cure cystic fibrosis. 

The COVID-19 pandemic negatively affected the health of human beings and changes their lifestyle, due to the imposed lockdowns. The increasing prevalence of respiratory disorders is creating the risk of cystic fibrosis. Patients affected by cystic fibrosis are at high risk of being infected by the virus. Other complications related to cystic fibrosis such as lung infection, cystic fibrosis-related diabetes, and inflammation of the pancreas gained attention of key players, who are engaged in the development of drugs and for fast recovery of patients across the globe.

  • Increasing demand for treatment alternatives, due to the rising prevalence of CF, is expected to drive the market.
  • Rising adoption of drug therapies is projected to propel the market during the forecast period.
  • High cost of surgical treatment is anticipated to hinder the market.
  • Low awareness in developing nations regarding the disease is expected to hamper the market in the coming years.
  • Research and development activities are projected to create lucrative opportunities for market players. 

Scope of the Report

The report on the global cystic fibrosis market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Cystic Fibrosis Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2021

Historic Data

2019–2020

Forecast Period

2022–2030

Segmentation

Diagnosis Types (Sweat Test, Genetic Test, Newborn Screening, Sinus X-rays, Lung Function Tests, Intestinal Current Measurement, Nasal Potential Difference, Sputum Culture, and Chest X-rays), and Treatment Methods (Lung Transplant, Bowel Surgery, Feeding Tube, Noninvasive Ventilation, Oxygen Therapy, and Liver Transplant)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Bayer AG; Pfizer Inc.; Mylan N.V; Gilead Sciences, Inc.; Novartis AG; AstraZeneca; AbbVie Inc.; and Vertex Pharmaceuticals Incorporated    

Market Segment Insights

Sweat test segment to expand at a considerable CAGR

On the basis of diagnosis types, the market is segregated into sweat test, genetic test, newborn screening, sinus X-rays, lung function tests, intestinal current measurement, nasal potential difference, sputum culture, and chest x-rays. The sweat test segment is projected to expand at a considerable CAGR during the forecast period, as it is the conclusive test for cystic fibrosis. Sweat test measures the amount of chloride present in body sweat, which is higher in patients who have cystic fibrosis. This test is not painful and does not use needle. The newborn screening segment is anticipated to account for a major market share during the forecast period, owing to the increasing testing of cystic fibrosis in newborns. 

Cystic Fibrosis Market_by Diagnosis

Bowel surgery segment to hold a significant share of the market

Based on treatment methods, the market is divided into lung transplant, bowel surgery, feeding tube, noninvasive ventilation, oxygen therapy, and liver transplant. The bowel surgery segment is expected to hold a significant share of the market in the coming years. Bowel surgery is used to remove blockages in intestine, by using laparoscope. The lung transplant segment accounts for a significant market share. The transplantation of lung is done to replace the one or both diseased lungs from a human donor with healthy lungs. The lung transplantation is reserved for patients who have tired other medications but their condition has not satisfactorily improved. 

North America is anticipated to constitute a key market share

In terms of regions, the cystic fibrosis market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to constitute a key share of the market during the forecast period, owing to increasing prevalence of diseases and rising adoption of advanced drugs for good outcomes. The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period, due to rising healthcare facilities and high awareness associated with treatment of cystic fibrosis.

Cystic Fibrosis Market

Segments

The global cystic fibrosis market has been segmented on the basis of

Diagnosis
  • Sweat Test
  • Genetic Test
  • Newborn Screening
  • Sinus X-rays
  • Lung Function Tests
  • Intestinal Current Measurement
  • Nasal Potential Difference
  • Sputum Culture
  • Chest X-rays
Treatment Methods
  • Lung Transplant
  • Bowel Surgery
  • Feeding Tube
  • Noninvasive Ventilation
  • Oxygen Therapy
  • Liver Transplant
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Bayer AG
  • Pfizer Inc.
  • Mylan N.V
  • Gilead Sciences, Inc.
  • Novartis AG
  • AstraZeneca
  • AbbVie Inc.
  • Vertex Pharmaceuticals Incorporated   

Competitive Landscape

Key players competing in the global cystic fibrosis market are Bayer AG; Pfizer Inc.; Mylan N.V; Gilead Sciences, Inc.; Novartis AG; AstraZeneca; AbbVie Inc.; and Vertex Pharmaceuticals Incorporated.   
Many key players adopted organic growth strategies including product launches, advancements in technology and participation in events. These companies focus on development of drugs, and adopt acquisitions & collaborations to boost their market share.

Cystic Fibrosis Market_Key Players

Frequently Asked Questions

Key players competing in the global cystic fibrosis market are Bayer AG; Pfizer Inc.; Mylan N.V; Gilead Sciences, Inc.; Novartis AG; AstraZeneca; AbbVie Inc.; and Vertex Pharmaceuticals Incorporated.

The global cystic fibrosis market is anticipated to expand at a CAGR of 24.6% during the forecast period, 2022–2030.

Increasing demand for treatment alternatives, due to the rising prevalence of CF, is expected to drive the market.

The global cystic fibrosis market size was valued at USD 5.16 billion in 2021, is estimated to reach USD 31.91 billion by 2030 during the forecast period, 2022–2030.

North America is expected to constitute a key share of the market during the forecast period.

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cystic Fibrosis Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Cystic Fibrosis Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Cystic Fibrosis Market - Supply Chain
  4.5. Global Cystic Fibrosis Market Forecast
     4.5.1. Cystic Fibrosis Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Cystic Fibrosis Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Cystic Fibrosis Market Absolute $ Opportunity
5. Global Cystic Fibrosis Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Cystic Fibrosis Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Cystic Fibrosis Demand Share Forecast, 2019-2026
6. North America Cystic Fibrosis Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Cystic Fibrosis Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Cystic Fibrosis Demand Share Forecast, 2019-2026
7. Latin America Cystic Fibrosis Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Cystic Fibrosis Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Cystic Fibrosis Demand Share Forecast, 2019-2026
8. Europe Cystic Fibrosis Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Cystic Fibrosis Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Cystic Fibrosis Demand Share Forecast, 2019-2026
9. Asia Pacific Cystic Fibrosis Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Cystic Fibrosis Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Cystic Fibrosis Demand Share Forecast, 2019-2026
10. Middle East & Africa Cystic Fibrosis Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Cystic Fibrosis Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Cystic Fibrosis Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Cystic Fibrosis Market: Market Share Analysis
  11.2. Cystic Fibrosis Distributors and Customers
  11.3. Cystic Fibrosis Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Bayer AG
     11.4.2. Pfizer Inc.
     11.4.3. Mylan N.V
     11.4.4. Gilead Sciences, Inc.
     11.4.5. Novartis AG
     11.4.6. AstraZeneca
     11.4.7. AbbVie Inc.
     11.4.8. Vertex Pharmaceuticals Incorporated   

Methodology

Our Clients

Dassault Aviation
Nestle SA
The John Holland Group
Honda Motor Co. Ltd.
sinopec
FedEx Logistics
Siemens Healthcare
Microsoft